Effect of Clemastine Fumarate on Color Vision in Healthy Controls

Completed · Phase 1

Conditions studied: Healthy Subjects

In brief

In a1972 study in the French Annals of Pharmaceuticals, Laroche and Laroche reported that the drug clemastine has a negative effect on patients' color discrimination, which is the ability to distinguish different hues and arrange them in the correct order. In an upcoming clinical trial studying the effect of clemastine on vision outcomes, our lab aims to assess color visual performance adding assessment of color defectiveness as a clinical endpoint. Color defectiveness is the ability to see certain colors, and is commonly referred to as color-blindness. Color discrimination and defectiveness can be related, but do not always correlate. This study aims to detect the effect, if any, that clemastine has on color defectiveness in healthy controls, which could confound its use as an outcome endpoint in future clinical trials relating to clemastine.

Key facts

Study ID

NCT02613091

Run by

University of California, San Francisco

People needed

23

Starts

2016-04-01

Last updated by the study team

2016-11-03

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy control

You may not qualify if…

• Preexisting ophthalmologic conditions such as optic neuritis, macular star, glaucoma

Where it is running

• Sandler Neurosciences Building, Neurological Clinical Research Unit — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.